+Vote!
Medical News Today (Free subscription) | 25/08/2008
The following summarizes recent efforts and initiatives that seek to reduce racial health disparities. Charles County, Md.: Ministers Alliance of Charles County and Vicinity; local health officials; Claudia Baquet, a doctor and specialist in health disparities at the University of Maryland School of Medicine; and state Sen.
1Vote!
Medical News Today (Free subscription) | 24/08/2008
Two independent research groups have found that simultaneous inhibition of two signaling pathways resulted in substantially enhanced antitumor effects in mouse models of prostate and breast cancer. In an accompany commentary, Steven Grant, at Virginia Commonwealth University Health Science Center, Richmond, discusses the clinical importance of these studies and highlights some of the questions that...
1Vote!
Medical News Today (Free subscription) | 05/08/2008
Men age 75 and older should not be screened for prostate cancer, and younger men should discuss the benefits and harms of the prostate-specific antigen (PSA) test with their clinicians before being tested, according to a new recommendation from the U.S. Preventive Services Task Force. The recommendation and accompanying evidence summary appear in the August 5 issue of the Annals of Internal Medicine....
+Vote!
Medical News Today (Free subscription) | 22/07/2008
Scientists at The Institute of Cancer Research have found that the partnering of two genes could be responsible for up to 600 British men developing a drug resistant and potentially deadly form of prostate cancer each year. The international study, published in the British Journal of Cancer, also outlines the discovery of a new prostate cancer gene, ACSL3.
+Vote!
Medical News Today (Free subscription) | 17/07/2008
Researchers at The University of Nottingham have shown an association between certain past diagnostic radiation procedures and an increased risk of young-onset prostate cancer - a rare form of prostate cancer which affects about 10 per cent of all men diagnosed with the disease.
+Vote!
Medical News Today (Free subscription) | 30/06/2008
ORLANDO, FL (UroToday.com) - Dr. Abraham Morgentaler and colleagues examined the relationship between testosterone (T) levels and PSA in hypogonadal men. 184 patients with symptomatic hypogonadism (T
+Vote!
Medical News Today (Free subscription) | 30/06/2008
ORLANDO, FL (UroToday.com) - Canadian investigators created a teaching and mentoring method called "block" surgery to simplify and improve time efficiency and safety while maintaining acceptable oncological and functional outcomes during the learning curve of a laparoscopic radical prostatectomy (LRP). The LRP was broken down into 10 key "blocks" assigned different levels of difficulty. Practicing...
+Vote!
Medical News Today (Free subscription) | 28/06/2008
ORLANDO, FL (UroToday.com) - The AUA and American Cancer Society advocate offering men annual screening with serum PSA and DRE starting at age 50 years in the general population and earlier in high-risk men. In studies to examine whether lung cancer screening is beneficial, an important feature of using CT screening was that the screening regimen must be strictly adhered to in order to detect important...
+Vote!
Medical News Today (Free subscription) | 27/06/2008
ORLANDO, FL (UroToday.com) - With the incidence of robotic-assisted radical prostatectomy (RALP) increasing, questions regarding the significance of margin status have arisen. Patients with a history of a prior transurethral resection of the prostate (TURP), may have a higher incidence of positive margins because of the prior surgery.
+Vote!
Medical News Today (Free subscription) | 26/06/2008
ORLANDO, FL (UroToday.com) - Blood loss in radical prostatectomies has been an issue for a long time. New operative techniques led to an optimization regarding not only nerve sparing but also blood sparing attempts. These investigators prospectively studied the influence of the training level of the assisting doctor regarding blood loss in radical prostatectomies. 364 patients underwent radical prostatectomy...
+Vote!
Medical News Today (Free subscription) | 26/06/2008
ORLANDO, FL (UroToday.com) - Recent reports suggest that men with higher BMI have lower PSA concentrations due to dilution of a set PSA amount by a larger plasma volume. The study published in JAMA in November of 2007, drew such conclusion from a cohort of men that had a known diagnosis of prostate cancer (and went on to prostatectomy). The current report by Grubb and colleagues substantiates the findings...
+Vote!
Medical News Today (Free subscription) | 24/06/2008
ORLANDO, FL (UroToday.com) - The use of HIFU in localized prostate cancer (PCa) is an emerging minimally-invasive technology that offers the potential fewer side-effects and effective cancer control. Visually-directed HIFU for the conduct of therapy for the Sonablate®500 device allows the user to change energy levels per pulse based on real-time greyscale ultrasound feedback.
+Vote!
Medical News Today (Free subscription) | 18/06/2008
The findings of a US pilot study on men with low risk prostate cancer suggests that following an intensive healthy diet and lifestyle regime emphasizing low meat and high vegetable and fruit intake, regular exercise, yoga stretching, meditation and support group participation, can change the way that genes behave and alter the progress of cancer, for instance by switching on tumor killers and turning...
+Vote!
Medical News Today (Free subscription) | 11/06/2008
ORLANDO, FL (UroToday.com) - The presence of positive surgical margins in a radical prostatectomy (RP) specimen is an important negative prognostic factor, although the length of the positive margins was not an independent predictive factor for biochemical recurrence (BCR) in most studies. The aim of this study is to correlate the length and the Gleason grade of the positive resection margin with BCR...
+Vote!
Medical News Today (Free subscription) | 11/06/2008
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced that, following recent communications with the U.S. Food and Drug Administration (FDA), the Company is commencing its Phase 3 development program for NX-1207, Nymox's investigational product for the treatment of benign prostatic hyperplasia (BPH). The Company will begin Phase 3 clinical trials in the U.S. later this year to support a New Drug...
